Benzodiazepines use in Morocco: A nation wide consumption database study between 2004 and 2017
| Autor: | Zineb Qmichou, Yahia Cherrah, Hassan Sefrioui, Zidane Qriouet, Abdelmajid Belaiche |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Zolpidem
Databases Factual medicine.drug_class Population Benzodiazepines 03 medical and health sciences 0302 clinical medicine Environmental health Humans Medicine education General Psychology Zopiclone education.field_of_study Benzodiazepine Bromazepam business.industry Lorazepam General Medicine 030227 psychiatry Morocco Psychiatry and Mental health Alprazolam Nordazepam business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Asian Journal of Psychiatry. 47:101852 |
| ISSN: | 1876-2018 |
| Popis: | Although information exists regarding the rate of benzodiazepines (BZDs) use in different countries, little information is available concerning the BZDs consumption in Morocco. To describe prescription rate in Morocco, a retrospective descriptive analysis of BZDs and their agonists use with the instituteIQIVIA database was performed during the period 2004-2017. The obtained data provide a dynamic approach to total BZDs consumption using an annual collection of sales data in Morocco and were expressed in terms of daily defined doses/ 1000 inhabitants / day. Data analysis showed that the major BZDs sold in Morocco were Alprazolam, Bromazepam, Nordazepam, Lorazepam, Parazepam, Diazepam and two benzodiazepine agonists, Zolpidem and Zopiclone. The Bromazepam was the molecule the most consumed during 2004-2016. In 2017, Alprazolam was the most consumed followed by Bromazepam, Nordazepam, Zolpidem, Lorazepam, Parazepam, Diazepam, Dipotassium clorazepate, Dipotassium Clorazypate and Zopiclone with 0.94, 0.91, 0.6, 0.55, 0.45, 0.32, 0.18, 0.18, 0.07 and 0.05 daily defined doses/ 1000 inhabitants / day respectively. The total amount consumed each year for all BZDs and their agonists in Morocco was 2.69, 2.77, 3, 3.17, 3.32, 3.54, 3.61, 3.81, 4.06, 4.30, 4.06, 3.94, 3.78 and 3.66 daily defined doses/ 1000 inhabitants / day, respectively during 2004-2017. To our knowledge, this is the first study that describes the consumption of BZDs and their agonists (Zolpidem, Zopiclone) in Morocco. This data may help the analytical toxicology laboratory and health organizations operating in the field of analytical biochemistry to develop specific BZDs quantification and detection methods needed for the Moroccan population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect